Showing results (191-200 of 282) with videos related to
Sort By:
Pageof 29
Hemasphere|July 11, 2020
Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical TrialsJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2018
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström MacroglobulinemiaSteven P Treon, Joshua Gustine, Kirsten Meid, et al.Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.Pageof 29